Kenneth P. Johnson Memorial Lecture
ACTRIMS is proud to present an annual lecture named in honor of the late Kenneth P. Johnson, MD, who spearheaded the foundation of ACTRIMS®. The lecture provides an opportunity to hear from a prestigious clinician or researcher selected for their knowledge, accomplishments and contributions related to Multiple Sclerosis. To learn more about Kenneth P. Johnson and past lecturers, click here.
Rhonda Voskuhl, MD from the University of California, Los Angeles will present the 2019 Kenneth P. Johnson Memorial Lecture.
2019 Lecuturer: Dr. Rhonda Voskuhl
Dr. Rhonda Voskuhl went to medical school at Vanderbilt University in Nashville, TN, followed by neurology residency at the University of Texas Southwestern in Dallas, TX. She did a post doctoral fellowship in the Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke (NINDS) within the National Institutes of Health (NIH) in Bethesda, MD which focused on research in MS patients as well as in the animal model for MS. She became faculty at the University of California, Los Angeles in 1995. Dr. Voskuhl was the recipient of the prestigious Harry Weaver Award from the National Multiple Sclerosis Society in 1997, and received the Jack H. Skirball Endowed Chair in Multiple Sclerosis Research in 2006. Dr. Voskuhl is a Professor in UCLA's Department of Neurology and is Director of the UCLA MS Program. She has received numerous grants from both the National Institutes of Health and the National Multiple Sclerosis Society.
Dr. Voskuhl’s laboratory is focused upon understanding the immunopathogenesis and neurodegenerative component of MS through use of the murine model experimental autoimmune encephalomyelitis (EAE). She does basic science and novel clinical trial design. She has studied the effect of sex hormones and sex chromosomes on both inflammation and neurodegeneration. This basic research has led to four novel treatment trials in MS. A current focus is to make basic discoveries in neuroprotection for translation to novel therapies in MS and other neurodegeneratitve diseases.